<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003Kr Cp q8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230928000929&amp;fc=20230708114047&amp;utm_source= Chrome&amp;utm_medium =rss<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230928000929&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 28 日星期四 04:09:31 +0000</lastbuilddate><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>经皮冠状动脉介入治疗后吸烟与心血管结局：一项韩国研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37757448/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>结论：吸烟与接受 PCI 的患者不良结局风险较高相关。PCI 后 PY 小于 20 的戒烟者的风险与不吸烟者相当。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 26:ehad616.doi: 10.1093/eurheartj/ehad616. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：作者调查了经皮冠状动脉介入治疗（PCI）后吸烟和戒烟对心血管结局的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：利用韩国国民健康保险系统的全国数据库，根据一年内第一次健康检查时的吸烟状况，将 2009 年至 2016 年间接受 PCI 的 74 471 名患者分为非吸烟者、前吸烟者或当前吸烟者。 PCI后主要结局是主要不良心脑血管事件（MACCE），这是一种由全因死亡、心肌梗死、冠状动脉血运重建和卒中组成的复合事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 4.0 年的随访期间，当前吸烟者的 MACCE 发生率比不吸烟者高 19.8% [调整后风险比 (aHR) 1.198；95% 置信区间 (CI) 1.137-1.263]，戒烟者倾向于与非吸烟者的戒烟率相当（aHR 1.036；95% CI .992-1.081）。对 31 887 名 PCI 术前和术后健康检查数据的患者进行了戒烟效果分析。在PCI后停止吸烟的戒烟者中，累积吸烟暴露&lt;20包年（PYs）的戒烟者的MACCE率往往与持续不吸烟者相当。然而，累积暴露≥20包年（PYs）的戒烟者的MACCE率PY 与持续吸烟者相当[aHR (95% CI) &lt;10 PY，1.182 (.971-1.438)；10-20 PY 1.114 (.963-1.290)；20-30 PY 1.206 (1.054-1.380) ；≥ 30 PY 1.227 (1.113-1.352)；与持续不吸烟者相比，持续吸烟者分别为 1.223 (1.126-1.328)，交互作用 P &lt;.001]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：吸烟与接受 PCI 的患者不良结局风险较高相关。PCI 后 PY 小于 20 的戒烟者的风险与不吸烟者相当。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37757448/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37757448</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad616>10.1093/eurheartj/ehad616</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37757448</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>基友正</dc:creator><dc:creator>韩京道</dc:creator><dc:creator>金孝秀</dc:creator><dc:creator>韩正奎</dc:creator><dc:date>2023-09-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>经皮冠状动脉介入治疗后吸烟与心血管结局：一项韩国研究</dc:title><dc:identifier>下午：37757448</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad616</dc:identifier></item><item><title>后壁隔离在持续性心房颤动和收缩性心力衰竭导管消融中的作用：随机临床试验的二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37755920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>结论和相关性：本研究的结果表明，在 PVI 的基础上添加 PWI 并不能改善持续性 AF 和症状性 HFrEF 患者的心律失常复发或 LVEF 恢复。无论消融如何，导管消融与收缩功能的显着改善相关这些结果提醒我们不要将 PWI 常规纳入因持续性 AF 进行首次导管消融的 HFrEF 患者中。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 27 日。doi：10.1001/jamacardio.2023.3208。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：与药物治疗相比，房颤 (AF) 和射血分数降低的心力衰竭 (HFrEF) 患者的导管消融可改善左心室射血分数 (LVEF) 和生存率。非随机研究报告后壁隔离可提高成功率（PWI）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：确定肺静脉隔离 (PVI) 联合 PWI 与单独 PVI 对 HFrEF 患者预后的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这是对 CAPLA 试验的临时二次分析，该试验是一项多中心、前瞻性、随机对照试验，涉及 3 个国家（澳大利亚、加拿大和英国）的 11 个中心。CAPLA 纳入了 338 名持续性 AF 患者随机分为 PVI 加 PWI 或单独 PVI。该亚组研究纳入了原始 CAPLA 研究中患有症状性 HFrEF 的患者（LVEF &lt;50% 且纽约心脏协会分级≥II）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预措施：使用 PWI 进行肺静脉隔离与单独使用 PVI 进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和措施：主要终点是在单次消融手术后，在 12 个月内未使用抗心律失常药物 (AAD) 治疗时，没有任何记录在案的超过 30 秒的房性心律失常。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共确定了 98 名患有持续性 AF 和症状性 HFrEF 的患者（平均 [SD] 年龄，62.1 [9.8] 岁；79.5% 为男性；基线时平均 [SD] LVEF，34.6% [7.9%]）。 12 个月后，在不使用 AAD 治疗的情况下，PVI 联合 PWI 患者中有 58.7% 的患者没有复发性房性心律失常，而单独使用 PVI 的患者这一比例为 61.5%（风险比，1.02；95% CI，0.54-1.91；P = .96）。多次手术后，无论是否接受 AAD 治疗，房性心律失常的发生率均无显着差异（PVI 加 PWI 与单独 PVI，60.9% vs 65.4%；P = .73）或 AF 负担（两组中中位数均为 0%；P = . 78). PVI 加 PWI 的平均 LVEF 显着改善 (Δ LVEF, 19.3% [13.0%; P &lt; .01) 和单独 PVI (18.2% [14.1%; P &lt; .01)]，组间无差异 (P = .71). PVI 加 PWI 组中 65.2% 的患者出现左室功能正常化，而单独 PVI 组中这一比例为 50.0% (P = .13)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：本研究的结果表明，在 PVI 的基础上添加 PWI 并不能改善持续性 AF 和症状性 HFrEF 患者的心律失常复发或 LVEF 恢复。无论消融如何，导管消融与收缩功能的显着改善相关这些结果提醒我们不要将 PWI 常规纳入因持续性 AF 进行首次导管消融的 HFrEF 患者中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试用注册：http://anzctr.org.au 标识符：ACTRN12616001436460。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37755920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37755920</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3208>10.1001/jamacardio.2023.3208</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37755920</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>杰里米·威廉</dc:creator><dc:creator>钱大卫</dc:creator><dc:creator>哈里哈兰·苏古玛</dc:creator><dc:creator>凌良瀚</dc:creator><dc:creator>路易丝·塞根</dc:creator><dc:creator>罗斯·克劳利</dc:creator><dc:creator>艾哈迈德·凯西</dc:creator><dc:creator>约书亚·霍森</dc:creator><dc:creator>桑迪普·帕布</dc:creator><dc:creator>亚历山大·沃斯科博尼克</dc:creator><dc:creator>杰弗里·黄</dc:creator><dc:creator>约瑟夫·B·莫顿</dc:creator><dc:creator>杰弗里·李</dc:creator><dc:creator>亚历克斯·J·麦克莱伦</dc:creator><dc:creator>黄明德</dc:creator><dc:creator>拉吉夫·K·帕塔克</dc:creator><dc:creator>劳伦斯·斯特恩斯</dc:creator><dc:creator>马修·金克斯</dc:creator><dc:creator>克里斯托弗·里德</dc:creator><dc:creator>普拉山坦·桑德斯</dc:creator><dc:creator>乔纳森·M·卡尔曼</dc:creator><dc:creator>彼得·M·基斯特勒</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>后壁隔离在持续性心房颤动和收缩性心力衰竭导管消融中的作用：随机临床试验的二次分析</dc:title><dc:identifier>下午:37755920</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3208</dc:identifier></item><item><title>血管紧张素-脑啡肽酶抑制剂在射血分数中的经济评价</title><link/>https://pubmed.ncbi.nlm.nih.gov/37755820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 27 日。doi：10.1001/jamacardio.2023.3223。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37755820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37755820</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3223>10.1001/jamacardio.2023.3223</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37755820</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>劳拉·P·科恩</dc:creator><dc:creator>布兰登·K·贝洛斯</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>血管紧张素-脑啡肽酶抑制剂在射血分数中的经济评价</dc:title><dc:identifier>下午：37755820</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3223</dc:identifier></item><item><title>沙库巴曲缬沙坦治疗心力衰竭的健康和经济评价</title><link/>https://pubmed.ncbi.nlm.nih.gov/37755814/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>结论和相关性：成本效益模型提供了沙库巴曲缬沙坦与 RASis 治疗的 ICER，与 EF 降低和轻度降低 (≤50%) 的患者的高经济价值一致，并且以当前未贴现的批发采购成本价格至少具有中间价值EF 为 60% 或更低。在较低 EF 范围内，治疗更具成本效益。这些发现可能对当代临床实践中的承保决策和价值评估产生影响…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 27 日。doi：10.1001/jamacardio.2023.3216。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：美国食品和药物管理局将沙库巴曲缬沙坦的标签范围从射血分数 (EF) 降低的慢性心力衰竭 (HF) 患者的治疗范围扩大到所有 HF 患者，并指出 EF 低于正常的患者获益最大然而，低于正常值的上限尚未明确定义，并且更广泛的 EF 范围内的值确定也是未知的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估沙库巴曲缬沙坦与肾素血管紧张素系统抑制剂 (RASis) 在不同 EF 上限水平上的成本效益。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：该经济评估包括来自 PARADIGM-HF（ARNI 与 ACEI 的前瞻性比较，以确定对心力衰竭全球死亡率和发病率的影响）和 PARAGON-HF（ARNI 与 ACEI 的前瞻性比较）的参与者级数据ARB 在保留射血分数的 HF 方面的全球结果）试验。PARADIGM-HF 于 2009 年至 2014 年期间进行，PARAGON-HF 于 2014 年至 2019 年期间进行，该分析于 2021 年至 2023 年期间进行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：5 状态马尔可夫模型使用 PARADIGM-HF 和 PARAGON-HF 降低全因死亡率和心衰住院风险。根据 EuroQol-5D 评分估计生活质量差异。住院和药物费用从公布的国家来源获得；沙库巴曲缬沙坦的批发采购成本为每年 7092 美元。风险估计和治疗效果以连续 5% EF 增量至 60% 生成，并应用于来自 Get 的美国心力衰竭患者的 EF 分布根据心力衰竭指南注册。基本案例包括从医疗保健部门角度来看的终生范围。增量成本效益比 (ICER) 是在 EF 为 60% 或更低（基本案例）以及各种较高水平 EF 时估计的截止。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在分析数据的 13 264 名患者中，对于 EF 为 60% 或更低的患者，与 RASi 相比，沙库巴曲缬沙坦预计将增加 0.53 质量调整生命年 (QALY)，增量终生成本为 40 892 美元，产生每 QALY 的 ICER 为 76 852 美元。在概率敏感性分析中，95% 的 ICER 值发生在每 QALY 71 516 美元到 82 970 美元之间。在慢性 HF 且 EF 为 60% 或更低的患者中，与 RASis 相比，沙库巴曲缬沙坦治疗至少具有中等经济价值（ICER &lt; 180 000 美元/QALY），沙库巴曲-缬沙坦每年成本为 10 242 美元或更少，具有高经济价值（ICER &lt; 60 000 美元/QALY）每年的成本为 3673 美元或更少，每年的成本节省为 338 美元或更少。当 EF 为 55% 或更低时，ICER 为每 QALY 67 331 美元、每 QALY 59 614 美元和每 QALY 56 786 美元，50仅对 EF 为 45% 或更高（最高≤60%）的患者使用沙库巴曲缬沙坦治疗，每获得 QALY 的 ICER 为 127 172 美元；治疗更具成本效益处于该范围下端的人（EF 为 45%-55% 的人，每 QALY 获得的 ICER 为 100 388 美元；EF 为 45%-50% 的人，每 QALY 获得的 ICER 为 84 291 美元）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：成本效益模型提供了沙库巴曲缬沙坦与 RASis 治疗的 ICER，与 EF 降低和轻度降低 (≤50%) 的患者的高经济价值一致，并且以当前未贴现的批发采购成本价格至少具有中间价值EF 为 60% 或更低。在较低 EF 范围内，治疗更具成本效益。这些发现可能对当代临床实践指南中的承保决策和价值评估产生影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37755814/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37755814</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3216>10.1001/jamacardio.2023.3216</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37755814</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>安基特·巴特</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>布赖恩·L·克拉吉特</dc:creator><dc:creator>格雷格·C·福纳罗</dc:creator><dc:creator>米尔顿·帕克</dc:creator><dc:creator>马克·普费弗</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>沉贤</dc:creator><dc:creator>若阿金·克里斯蒂诺</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:creator>托马斯·加齐亚诺</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>沙库巴曲缬沙坦治疗心力衰竭的健康和经济评价</dc:title><dc:identifier>下午：37755814</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3216</dc:identifier></item><item><title> 1999-2020 年美国成人心脏、肾脏和代谢疾病的患病率和重叠情况</title><link/>https://pubmed.ncbi.nlm.nih.gov/37755728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>结论和相关性：这项队列研究发现，CRM 多重病态在美国成年人中越来越常见，且治疗不足，这凸显了协作和综合管理策略的重要性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 27 日。doi：10.1001/jamacardio.2023.3241。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：就个体而言，心脏、肾脏和代谢 (CRM) 疾病是死亡、残疾和医疗保健相关费用的常见且主要原因。但是，迄今为止，CRM 疾病共存的频率尚未得到全面表征。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：调查当前和一段时间内美国成年人 CRM 状况的患病率和重叠情况。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：为了确定 CRM 状况的患病率，本队列研究评估了 2015 年 1 月至 2020 年 3 月全国健康和营养检查调查 (NHANES) 中包含的具有全国代表性的连续横截面数据。在CRM重叠中，比较了1999-2002年和2015-2020年之间的NHANES数据。包括11 607名未怀孕的美国成年人（≥20岁）的数据。数据分析发生在2020年11月10日至2022年11月23日之间。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：患有 CRM 疾病的参与者的比例，总体上按年龄分层，定义为心血管疾病 (CVD)、慢性肾病 (CKD)、2 型糖尿病 (T2D) 或全部 3 种疾病。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：从 2015 年到 2020 年 3 月，在分析中纳入的 11 607 名美国成年人中（平均 [SE] 年龄为 48.5 [0.4] 岁；51.0% 为女性），26.3% 的人至少患有 1 种 CRM 病症，8.0% 的人至少患有 2 种 CRM 病症。 CRM 病症，1.5% 的人有 3 种 CRM 病症。总体而言，CKD 加 T2D 是最常见的 CRM 二元组 (3.2%)，其次是 CVD 加 T2D (1.7%) 和 CVD 加 CKD (1.6%)。CRM 合并症较高的参与者负担更可能是年龄较大的男性。在 65 岁或以上的参与者中，33.6% 有 1 种 CRM 病症，17.1% 有 2 种 CRM 病症，5.0% 有 3 种 CRM 病症。在这个子集中，CKD 加 T2D（7.3%） ) 最常见，其次是 CVD 加 CKD (6.0%) 和 CVD 加 T2D (3.8%)。在报告非西班牙裔黑人种族或族裔、失业、低就业状况和无高收入的参与者中，CRM 合并症负担过高。在患有 3 种 CRM 病症的参与者中，近三分之一 (30.5%) 没有报告使用他汀类药物，只有 4.8% 和 3.0% 的人分别使用胰高血糖素样肽 1 受体激动剂和钠-葡萄糖协同转运蛋白 2 抑制剂。 1999 年至 2020 年间，患有多种 CRM 病症的美国成年人比例显着增加（从 5.3% 增至 8.0%；趋势 P &lt; .001），同时患有全部 3 种 CRM 病症的比例也显着增加（从 0.7% 增至 1.5%；P &lt; .001） .001 为趋势）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：这项队列研究发现，CRM 多重病态在美国成年人中越来越常见，且治疗不足，这凸显了协作和综合管理策略的重要性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37755728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37755728</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3241>10.1001/jamacardio.2023.3241</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37755728</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>约翰·W·奥斯特罗明斯基</dc:creator><dc:creator>苏珊娜·V·阿诺德</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>格雷格·C·福纳罗</dc:creator><dc:creator>杰米·赫希</dc:creator><dc:creator>斯韦塔·R·帕利</dc:creator><dc:creator>邦妮·MK·多纳托</dc:creator><dc:creator>克里斯蒂娜·M·帕里内洛</dc:creator><dc:creator>托马斯·奥康奈尔</dc:creator><dc:creator>埃里克·B·柯林斯</dc:creator><dc:creator>乔纳森·J·伍利</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>1999-2020 年美国成人心脏、肾脏和代谢疾病的患病率和重叠情况</dc:title><dc:identifier>下午：37755728</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3241</dc:identifier></item><item><title>规则的暴政</title><link/>https://pubmed.ncbi.nlm.nih.gov/37755723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 27 日。doi：10.1001/jamacardio.2023.3226。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37755723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37755723</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3226>10.1001/jamacardio.2023.3226</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37755723</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>罗纳德·W·德沃金</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>规则的暴政</dc:title><dc:identifier>下午：37755723</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3226</dc:identifier></item><item><title>生活方式因素对心血管健康和疾病中白细胞的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37752350/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>运动、压力、睡眠和饮食是影响心血管系统的四个截然不同但又相互交织的生活方式因素。大量的流行病学、临床和临床前研究强调了控制压力、保持良好的睡眠卫生、负责任的饮食习惯和定期锻炼的重要性。我们与生俱来具有可以保护我们免受特定疾病或使我们容易患某种特定疾病的基因蓝图。然而，生活方式因素建立在这些因素的基础上，并对其产生深远的影响…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Sep 26. doi: 10.1038/s41569-023-00931-w. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">运动、压力、睡眠和饮食是影响心血管系统的四个截然不同但又相互交织的生活方式因素。大量的流行病学、临床和临床前研究强调了控制压力、保持良好的睡眠卫生、负责任的饮食习惯和定期锻炼的重要性。我们与生俱来具有可以保护我们免受特定疾病或使我们易患某种特定疾病的蓝图。然而，生活方式因素会建立在这些易感性的基础上并对其产生深远的影响。过去 10 年的研究表明，总体免疫系统，特别是白细胞特别容易受到这些疾病的影响。环境扰动。压力、睡眠、饮食和运动等生活方式因素会影响白细胞的行为和功能，从而影响整个免疫系统。在这篇综述中，我们探讨了生活方式因素在背景下调节造血和白细胞迁移和功能的各种机制。我们特别关注神经系统作为将环境影响与白细胞行为联系起来的关键执行者的作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37752350/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37752350</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00931-w>10.1038/s41569-023-00931-w</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37752350</guid><pubDate> Tue, 26 Sep 2023 06:00:00 -0400</pubDate><dc:creator>亨利克·詹森</dc:creator><dc:creator>劳拉·科科克</dc:creator><dc:creator>菲利普·K·斯维尔斯基</dc:creator><dc:date>2023-09-26</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>生活方式因素对心血管健康和疾病中白细胞的影响</dc:title><dc:identifier>下午:37752350</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00931-w</dc:identifier></item><item><title>更年期过渡期与心血管风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37752349/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>更年期过渡期平均为末次月经前 2-8 年，与临床和亚临床心血管风险增加相关。在这篇综述中，我们讨论了更年期过渡期发生的代谢和心血管变化，以及卵巢衰老、时间性衰老和其他与衰老相关的危险因素在调节这些变化中的作用。解开时间性衰老和生殖衰老的相对贡献...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 26 日。doi：10.1038/s41569-023-00926-7。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">更年期过渡期平均为末次月经前 2-8 年，与临床和亚临床心血管风险增加相关。在这篇综述中，我们讨论了更年期过渡期发生的代谢和心血管变化，以及卵巢衰老、时间性衰老和其他与衰老相关的危险因素在调节这些变化中的作用。理清时间性衰老和生殖性衰老对心血管风险的相对影响具有挑战性，但对从绝经前过渡到绝经后的女性进行的纵向研究的数据表明，提供了宝贵的见解。我们还讨论了过早或提前绝经、手术绝经、血管舒缩和其他更年期症状如何改变心血管风险的证据。有针对性的干预措施是否可以减缓绝经过渡期间动脉粥样硬化和亚临床疾病的进展，从而延迟或预防心血管事件的发生仍有待确定。此外，我们考虑使用美国心脏协会改善和维持心血管健康的“生命基本 8 项关键措施”框架，为绝经过渡期女性降低心血管风险推荐策略，并讨论更年期激素治疗的心血管风险和益处。最后，我们还讨论了可能有益于该人群降低心血管风险的新疗法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37752349/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37752349</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00926-7>10.1038/s41569-023-00926-7</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37752349</guid><pubDate> Tue, 26 Sep 2023 06:00:00 -0400</pubDate><dc:creator>贾亚·M·梅塔</dc:creator><dc:creator>乔安·E·曼森</dc:creator><dc:date>2023-09-26</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>更年期过渡期与心血管风险</dc:title><dc:identifier>下午:37752349</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00926-7</dc:identifier></item><item><title> TMEM215 通过减弱 BIK 调节的 ER 向线粒体 Ca 流入来防止血管退化中的内皮细胞凋亡</title><link/>https://pubmed.ncbi.nlm.nih.gov/37750320/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>结论：TMEM215 通过下调 EZH2 由血流衍生的剪切应力诱导，可保护 EC 免受 BIK 触发的线粒体凋亡的影响，而这种凋亡是在血管修剪过程中钙通过线粒体相关 ER 膜流入介导的，从而为抗血管生成治疗提供了新的靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 26 日。doi：10.1161/CIRCRESAHA.123.322686。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在发育和病理组织中，血管生成产生的新生血管网络需要进一步修剪/回归，以通过凋亡和迁移删除无功能的内皮细胞（EC）。血管修剪期间 EC 凋亡的机制仍然难以捉摸。TMEM215（跨膜蛋白 215）是一种内质网定位的2次跨膜蛋白。我们之前已经证明ECs中TMEM215敲低会导致细胞死亡，但其生理功能和机制尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们通过免疫沉淀-质谱鉴定TMEM215的相互作用蛋白，表征了TMEM215在HUVEC细胞凋亡中的作用和机制，并通过建立条件敲除小鼠品系来评估TMEM215在EC细胞中的生理功能。通过肿瘤和脉络膜新生血管模型进行了评估。我们还尝试通过在体内使用纳米颗粒递送<i>Tmem215</i> siRNA 来评估其转化价值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：ECs 中<i>TMEM215</i>敲低诱导细胞凋亡。我们鉴定出分子伴侣 BiP 作为 TMEM215 的结合伴侣，TMEM215 与 BH（BCL-2 同源性）3-only 促凋亡蛋白 BIK 形成复合物并促进 BiP 的相互作用。 （BCL-2 相互作用杀手） <i>。TMEM215</i>敲低以 BIK 依赖性方式触发细胞凋亡，并被 BCL-2 消除。值得注意的是， <i>TMEM215</i>敲低增加了线粒体相关内质网膜的数量并缩短了距离，并增加了线粒体钙流入。通过阻断 IP <sub>3</sub> R（肌醇 1,4,5-三磷酸受体）或 MCU（线粒体钙单向转运蛋白）来抑制线粒体钙内流可消除<i>TMEM215</i>敲低诱导的细胞凋亡。EC 中的<i>TMEM215</i>表达是通过<i>EZH2</i>下调由生理层流剪切应力诱导的。在 EC 特异性<i>Tmem215</i>敲除小鼠中，诱导的<i>Tmem215</i>耗竭损害了视网膜脉管系统的退化，其特征是血管密度降低、空基膜套增加和 EC 细胞凋亡增加。此外，EC 特异性<i>Tmem215</i>消融抑制了血管系统破坏的肿瘤生长。然而，成年小鼠中<i>Tmem215</i>消融减弱了肺转移，这与<i>Vcam1</i>表达减少一致。携带<i>Tmem215</i> siRNA 的纳米颗粒的给药也抑制了肿瘤生长和脉络膜新生血管损伤。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论： <i>TMEM215</i>通过下调<i>EZH2</i>由血流衍生的剪切应力诱导，可保护内皮细胞免受 BIK 触发的线粒体凋亡的影响，而这种凋亡是在血管修剪过程中钙通过线粒体相关内质网膜流入介导的，从而为抗血管生成治疗提供了一个新的靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37750320/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37750320</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322686>10.1161/CIRCRESAHA.123.322686</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37750320</guid><pubDate> Tue, 26 Sep 2023 06:00:00 -0400</pubDate><dc:creator>张佩然</dc:creator><dc:creator>严宪春</dc:creator><dc:creator>张晓燕</dc:creator><dc:creator>刘元</dc:creator><dc:creator>冯星星</dc:creator><dc:creator>杨紫艳</dc:creator><dc:creator>张家玉林</dc:creator><dc:creator>徐新元</dc:creator><dc:creator>郑启军</dc:creator><dc:creator>梁梁</dc:creator><dc:creator>华汉</dc:creator><dc:date>2023-09-26</dc:date><dc:source>流通研究</dc:source><dc:title>TMEM215 通过减弱 BIK 调节的 ER 向线粒体 Ca 流入来防止血管退化中的内皮细胞凋亡</dc:title><dc:identifier>下午:37750320</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322686</dc:identifier></item><item><title>预康复：当代心脏手术中不断变化的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37749182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 25 日。doi：10.1038/s41569-023-00939-2。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37749182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37749182</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00939-2>10.1038/s41569-023-00939-2</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37749182</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿蒂里奥·巴贝托</dc:creator><dc:creator>丹尼尔·E·福尔曼</dc:creator><dc:date>2023-09-25</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>预康复：当代心脏手术中不断变化的作用</dc:title><dc:identifier>下午：37749182</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00939-2</dc:identifier></item><item><title>更正：2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南：美国心脏协会/美国心脏病学会临床实践指南联合委员会报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37747957/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 26 日；148(13):e148.doi: 10.1161/CIR.0000000000001183。Epub 2023 年 9 月 25 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37747957/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747957</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001183>10.1161/CIR.0000000000001183</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37747957</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>更正：2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南：美国心脏协会/美国心脏病学会临床实践指南联合委员会报告</dc:title><dc:identifier>下午:37747957</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001183</dc:identifier></item><item><title>透视 cGAMP 依赖性 PKG1 激活</title><link/>https://pubmed.ncbi.nlm.nih.gov/37747956/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 26 日；148(13):1035-1038.doi: 10.1161/CIRCULATIONAHA.123.066073.Epub 2023 年 9 月 25 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37747956/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747956</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066073>10.1161 / CIRCULATIONAHA.123.066073</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37747956</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乌尔里希·福斯特曼</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>透视 cGAMP 依赖性 PKG1 激活</dc:title><dc:identifier>下午:37747956</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066073</dc:identifier></item><item><title>他汀类药物可降低艾滋病毒患者患心脏病的风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37747955/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 26 日；148(13):1053-1054.doi: 10.1161/CIRCULATIONAHA.123.065357.Epub 2023 年 9 月 25 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37747955/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747955</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065357>10.1161/CIRCULATIONAHA.123.065357</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37747955</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>布里奇特·M·库恩</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>他汀类药物可降低艾滋病毒患者患心脏病的风险</dc:title><dc:identifier>下午:37747955</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065357</dc:identifier></item><item><title>国家首都权力动态的变化给医学研究带来了不确定性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37747954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 26 日；148(13):1055-1056. doi: 10.1161/CIRCULATIONAHA.123.066400. Epub 2023 年 9 月 25 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37747954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747954</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066400>10.1161 / CIRCULATIONAHA.123.066400</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37747954</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>谢丽尔·佩格斯</dc:creator><dc:creator>约翰·劳纳</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>国家首都权力动态的变化给医学研究带来了不确定性</dc:title><dc:identifier>下午：37747954</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066400</dc:identifier></item><item><title> Aldana-Bitar 等人关于文章“Alirocumab 和无症状家族性高胆固醇血症患者的冠状动脉粥样硬化：ARCHITECT 研究”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37747953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 26 日；148(13):1057. doi: 10.1161/CIRCULATIONAHA.123.065198. Epub 2023 年 9 月 25 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37747953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747953</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065198>10.1161/CIRCULATIONAHA.123.065198</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37747953</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>贾罗·阿尔达纳-比塔尔</dc:creator><dc:creator>罗纳德·P·卡尔斯伯格</dc:creator><dc:creator>马修·J·巴多夫</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>Aldana-Bitar 等人关于文章“Alirocumab 和无症状家族性高胆固醇血症患者的冠状动脉粥样硬化：ARCHITECT 研究”的信函</dc:title><dc:identifier>下午:37747953</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065198</dc:identifier></item><item><title> Pérez de Isla 等人对有关文章“Alirocumab 和无症状家族性高胆固醇血症患者的冠状动脉粥样硬化：ARCHITECT 研究”的回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37747952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928000929&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 26;148(13):1059-1060. doi: 10.1161/CIRCULATIONAHA.123.066276. Epub 2023 Sep 25.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37747952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747952</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066276>10.1161/CIRCULATIONAHA.123.066276</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37747952</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Leopoldo Pérez de Isla</dc:creator><dc:creator> Adriana Saltijeral Cerezo</dc:creator><dc:creator> Pedro Mata</dc:creator><dc:date> 2023-09-25</dc:date><dc:source> Circulation</dc:source><dc:title> Response by Pérez de Isla et al to Letter Regarding Article, &quot;Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study&quot;</dc:title><dc:identifier> pmid:37747952</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066276</dc:identifier></item><item><title> Expanding the Paradigm for Cardiovascular Palliative Care</title><link/> https://pubmed.ncbi.nlm.nih.gov/37747951/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928000929&amp;v=2.17.9.post6+86293ac<description> Cardiovascular disease (CVD) is the leading cause of death worldwide. Despite medical advances, patients with CVD experience high morbidity and mortality rates, affecting their quality of life and death. Among CVD conditions, palliative care has been studied mostly in patients with heart failure, where palliative care interventions have been associated with improvements in patient-centered outcomes, including quality of life, end-of-life care, and health care use. Although palliative care is now... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 26;148(13):1039-1052. doi: 10.1161/CIRCULATIONAHA.123.063193. Epub 2023 Sep 25.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Cardiovascular disease (CVD) is the leading cause of death worldwide. Despite medical advances, patients with CVD experience high morbidity and mortality rates, affecting their quality of life and death. Among CVD conditions, palliative care has been studied mostly in patients with heart failure, where palliative care interventions have been associated with improvements in patient-centered outcomes, including quality of life, end-of-life care, and health care use. Although palliative care is now incorporated into the American Heart Association/American College of Cardiology/Heart Failure Society of America guidelines for heart failure, the role of palliative care for non-heart failure CVD remains uncertain. Across all causes of CVD, palliative care can play an important role in all domains of CVD care from initial diagnosis to terminal care. In addition to general cardiovascular palliative care practices applicable to all areas, disease-specific palliative care needs may warrant individualized palliative care models. In this review, we discuss the role of cardiovascular palliative care for ischemic heart disease, valvular disease, arrhythmias, peripheral artery disease, and adult congenital heart disease. Although there are multiple barriers to cardiovascular palliative care, we recommend a framework for studying and developing cardiovascular palliative care models to improve patient-centered goal-concordant care for this underserved patient population.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37747951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747951</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063193>10.1161/CIRCULATIONAHA.123.063193</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37747951</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Sarah Godfrey</dc:creator><dc:creator> James N Kirkpatrick</dc:creator><dc:creator> Daniel B Kramer</dc:creator><dc:creator> Melanie S Sulistio</dc:creator><dc:date> 2023-09-25</dc:date><dc:source> Circulation</dc:source><dc:title> Expanding the Paradigm for Cardiovascular Palliative Care</dc:title><dc:identifier> pmid:37747951</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.063193</dc:identifier></item><item><title> Letter by Long and Jiang Regarding Article, &quot;Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study&quot;</title><link/> https://pubmed.ncbi.nlm.nih.gov/37747950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928000929&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 26;148(13):1058. doi: 10.1161/CIRCULATIONAHA.123.065391. Epub 2023 Sep 25.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37747950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37747950</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065391>10.1161/CIRCULATIONAHA.123.065391</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37747950</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Xingqing Long</dc:creator><dc:creator> Mingyang Jiang</dc:creator><dc:date> 2023-09-25</dc:date><dc:source> Circulation</dc:source><dc:title> Letter by Long and Jiang Regarding Article, &quot;Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study&quot;</dc:title><dc:identifier> pmid:37747950</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065391</dc:identifier></item><item><title> Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37746744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928000929&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.063444. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Type 2 diabetes (T2D) is associated with an increased risk of left ventricular dysfunction after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS). Persistent impairments in myocardial energetics and myocardial blood flow (MBF) may underpin this observation. Using phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance, this study tested the hypothesis that patients with severe AS and T2D (AS-T2D) would have impaired myocardial energetics as reflected by the phosphocreatine to ATP ratio (PCr/ATP) and vasodilator stress MBF compared with patients with AS without T2D (AS-noT2D), and that these differences would persist after AVR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Ninety-five patients with severe AS without coronary artery disease awaiting AVR (30 AS-T2D and 65 AS-noT2D) were recruited (71 years of age [69, 73]; 34 [37%] women). Thirty demographically matched healthy volunteers (HVs) and 30 patients with T2D without AS (T2D controls) were controls. One month before and 6 months after AVR, cardiac PCr/ATP, adenosine stress MBF, global longitudinal strain, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk distance were assessed in patients with AS. T2D controls underwent identical assessments at baseline and 6-month follow-up. HVs were assessed once and did not undergo 6-minute walk testing. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Compared with HVs, patients with AS (AS-T2D and AS-noT2D combined) showed impairment in PCr/ATP (median [interquartile range]; HVs, 2.15 [1.89, 2.34]; AS, 1.66 [1.56, 1.75]; <i>P</i> &lt;0.0001) and vasodilator stress MBF (HVs, 2.11 mL min g [1.89, 2.34]; AS, 1.54 mL min g [1.41, 1.66]; <i>P</i> &lt;0.0001) before AVR. Before AVR, within the AS group, patients with AS-T2D had worse PCr/ATP (AS-noT2D, 1.74 [1.62, 1.86]; AS-T2D, 1.44 [1.32, 1.56]; <i>P</i> =0.002) and vasodilator stress MBF (AS-noT2D, 1.67 mL min g [1.5, 1.84]; AS-T2D, 1.25 mL min g [1.22, 1.38]; <i>P</i> =0.001) compared with patients with AS-noT2D. Before AVR, patients with AS-T2D also had worse PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.66 [1.56, 1.75]; <i>P</i> =0.04) and vasodilator stress MBF (AS-T2D, 1.25 mL min g [1.10, 1.41]; T2D controls, 1.54 mL min g [1.41, 1.66]; <i>P</i> =0.001) compared with T2D controls at baseline. After AVR, PCr/ATP normalized in patients with AS-noT2D, whereas patients with AS-T2D showed no improvements (AS-noT2D, 2.11 [1.79, 2.43]; AS-T2D, 1.30 [1.07, 1.53]; <i>P</i> =0.0006). Vasodilator stress MBF improved in both AS groups after AVR, but this remained lower in patients with AS-T2D (AS-noT2D, 1.80 mL min g [1.59, 2.0]; AS-T2D, 1.48 mL min g [1.29, 1.66]; <i>P</i> =0.03). There were no longer differences in PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.51 [1.34, 1.53]; <i>P</i> =0.12) or vasodilator stress MBF (AS-T2D, 1.48 mL min g [1.29, 1.66]; T2D controls, 1.60 mL min g [1.34, 1.86]; <i>P</i> =0.82) between patients with AS-T2D after AVR and T2D controls at follow-up. Whereas global longitudinal strain, 6-minute walk distance, and NT-proBNP all improved after AVR in patients with AS-noT2D, no improvement in these assessments was observed in patients with AS-T2D. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37746744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37746744</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063444>10.1161/CIRCULATIONAHA.122.063444</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37746744</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Nicholas Jex</dc:creator><dc:creator> John P Greenwood</dc:creator><dc:creator> Richard M Cubbon</dc:creator><dc:creator> Oliver J Rider</dc:creator><dc:creator> Amrit Chowdhary</dc:creator><dc:creator> Sharmaine Thirunavukarasu</dc:creator><dc:creator> Sindhoora Kotha</dc:creator><dc:creator> Marilena Giannoudi</dc:creator><dc:creator> Anna McGrane</dc:creator><dc:creator> Amanda Maccannell</dc:creator><dc:creator> Marcella Conning-Rowland</dc:creator><dc:creator> Sam Straw</dc:creator><dc:creator> Henry Procter</dc:creator><dc:creator> Sotiris Papaspyros</dc:creator><dc:creator> Betsy Evans</dc:creator><dc:creator> Kalyana Javangula</dc:creator><dc:creator> Antonella Ferrara</dc:creator><dc:creator> Walid Elmahdy</dc:creator><dc:creator> Pankaj Kaul</dc:creator><dc:creator> Hui Xue</dc:creator><dc:creator> Peter Swoboda</dc:creator><dc:creator> Peter Kellman</dc:creator><dc:creator> Ladislav Valkovič</dc:creator><dc:creator> Lee Roberts</dc:creator><dc:creator> David Beech</dc:creator><dc:creator> Mark T Kearney</dc:creator><dc:creator> Sven Plein</dc:creator><dc:creator> Marc R Dweck</dc:creator><dc:creator> Eylem Levelt</dc:creator><dc:date> 2023-09-25</dc:date><dc:source> Circulation</dc:source><dc:title> Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis</dc:title><dc:identifier> pmid:37746744</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.063444</dc:identifier></item><item><title> Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37746718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928000929&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ-induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.062551. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We used an established murine ICI myocarditis model ( <i>Ctla4</i> <sup><i>+/-</i></sup> <i>Pdcd1</i> <sup><i>-/-</i></sup> mice) to explore the cardiac immune landscape using single-cell RNA-sequencing, immunostaining, flow cytometry, in situ RNA hybridization, molecular imaging, and antibody neutralization studies. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We observed marked increases in CCR2 (CC chemokine receptor type 2) <sup>+</sup> monocyte-derived macrophages and CD8 <sup>+</sup> T-cells in this model. The macrophage compartment was heterogeneous and displayed marked enrichment in an inflammatory CCR2 <sup>+</sup> subpopulation highly expressing <i>Cxcl9</i> (chemokine [CXC motif] ligand 9), <i>Cxcl10</i> (chemokine [CXC motif] ligand 10), <i>Gbp2b</i> (interferon-induced guanylate-binding protein 2b), and <i>Fcgr4</i> (Fc receptor, IgG, low affinity IV) that originated from CCR2 <sup>+</sup> monocytes. It is important that a similar macrophage population expressing <i>CXCL9</i> , <i>CXCL10</i> , and CD16α (human homologue of mouse FcgR4) was expanded in patients with ICI myocarditis. In silico prediction of cell-cell communication suggested interactions between T-cells and <i>Cxcl9</i> <sup><i>+</i></sup> <i>Cxcl10</i> <sup><i>+</i></sup> macrophages by IFN-γ (interferon gamma) and CXCR3 (CXC chemokine receptor 3) signaling pathways. Depleting CD8 <sup>+</sup> T-cells, macrophages, and blockade of IFN-γ signaling blunted the expansion of <i>Cxcl9</i> <sup><i>+</i></sup> <i>Cxcl10</i> <sup><i>+</i></sup> macrophages in the heart and attenuated myocarditis, suggesting that this interaction was necessary for disease pathogenesis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ-induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37746718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37746718</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062551>10.1161/CIRCULATIONAHA.122.062551</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37746718</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Pan Ma</dc:creator><dc:creator> Jing Liu</dc:creator><dc:creator> Juan Qin</dc:creator><dc:creator> Lulu Lai</dc:creator><dc:creator> Gyu Seong Heo</dc:creator><dc:creator> Hannah Luehmann</dc:creator><dc:creator> Deborah Sultan</dc:creator><dc:creator> Andrea Bredemeyer</dc:creator><dc:creator> Geetika Bajapa</dc:creator><dc:creator> Guoshuai Feng</dc:creator><dc:creator> Jesus Jimenez</dc:creator><dc:creator> Ruijun He</dc:creator><dc:creator> Antanisha Parks</dc:creator><dc:creator> Junedh Amrute</dc:creator><dc:creator> Ana Villanueva</dc:creator><dc:creator> Yongjian Liu</dc:creator><dc:creator> Chieh-Yu Lin</dc:creator><dc:creator> Matthias Mack</dc:creator><dc:creator> Kaushik Amancherla</dc:creator><dc:creator> Javid Moslehi</dc:creator><dc:creator> Kory J Lavine</dc:creator><dc:date> 2023-09-25</dc:date><dc:source> Circulation</dc:source><dc:title> Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis</dc:title><dc:identifier> pmid:37746718</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.062551</dc:identifier></item><item><title> Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials</title><link/> https://pubmed.ncbi.nlm.nih.gov/37746717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928000929&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: In patients with non-ST-segment-elevation myocardial infarction undergoing PCI, procedural anticoagulation with bivalirudin and heparin did not result in significantly different rates of mortality or ischemic events, including stent thrombosis and reinfarction. Bivalirudin reduced serious bleeding compared with heparin arising both from the access site and nonaccess sites. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.123.063946. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We performed an individual patient data meta-analysis of patients with non-ST-segment-elevation myocardial infarction in all 5 trials that randomized ≥1000 patients with any myocardial infarction undergoing PCI to bivalirudin versus heparin (MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY [Acute Catheterization and Urgent Intervention Triage Strategy], and BRIGHT). The primary effectiveness and safety end points were 30-day all-cause mortality and serious bleeding. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 12 155 patients were randomized: 6040 to bivalirudin (52.3% with a post-PCI bivalirudin infusion), and 6115 to heparin (53.2% with planned glycoprotein IIb/IIIa inhibitor use). Thirty-day mortality was not significantly different between bivalirudin and heparin (1.2% versus 1.1%; adjusted odds ratio, 1.24 [95% CI, 0.86-1.79]; <i>P</i> =0.25). Cardiac mortality, reinfarction, and stent thrombosis rates were also not significantly different. Bivalirudin reduced serious bleeding (both access site-related and non-access site-related) compared with heparin (3.3% versus 5.5%; adjusted odds ratio, 0.59; 95% CI, 0.48-0.72; <i>P</i> &lt;0.0001). Outcomes were consistent regardless of use of a post-PCI bivalirudin infusion or routine lycoprotein IIb/IIIa inhibitor use with heparin and during 1-year follow-up. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In patients with non-ST-segment-elevation myocardial infarction undergoing PCI, procedural anticoagulation with bivalirudin and heparin did not result in significantly different rates of mortality or ischemic events, including stent thrombosis and reinfarction. Bivalirudin reduced serious bleeding compared with heparin arising both from the access site and nonaccess sites.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37746717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928000929&v=2.17.9.post6+86293ac">37746717</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063946>10.1161/CIRCULATIONAHA.123.063946</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37746717</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Behnood Bikdeli</dc:creator><dc:creator> David Erlinge</dc:creator><dc:creator> Marco Valgimigli</dc:creator><dc:creator> Adnan Kastrati</dc:creator><dc:creator> Yaling Han</dc:creator><dc:creator> Philippe Gabriel Steg</dc:creator><dc:creator> Rod H Stables</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Stefan K James</dc:creator><dc:creator> Enrico Frigoli</dc:creator><dc:creator> Patrick Goldstein</dc:creator><dc:creator> Yi Li</dc:creator><dc:creator> Adeel Shahzad</dc:creator><dc:creator> Stefanie Schüpke</dc:creator><dc:creator> Ghazaleh Mehdipoor</dc:creator><dc:creator> Shmuel Chen</dc:creator><dc:creator> Björn Redfors</dc:creator><dc:creator> Aaron Crowley</dc:creator><dc:creator> Zhipeng Zhou</dc:creator><dc:creator> Gregg W Stone</dc:creator><dc:date> 2023-09-25</dc:date><dc:source> Circulation</dc:source><dc:title> Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials</dc:title><dc:identifier> pmid:37746717</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.063946</dc:identifier></item></channel></rss>